Healthcare Services

Cytokine Release Syndrome Management Market Developments and Growth Opportunities Across 2026–2030

March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Cytokine Release Syndrome Management Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The cytokine release syndrome management market size has seen significant growth over recent years. It is anticipated to increase from $23.76 billion in 2025 to $25.31 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.5%. This market’s expansion in previous periods can be linked to the rise of CAR-T therapies, the scarcity of CRS treatment choices, a reliance on corticosteroids, management primarily occurring in hospitals, and the elevated risk of mortality.

The market for cytokine release syndrome management is anticipated to show significant expansion in the coming years. It is predicted to reach $32.35 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.3%. This expansion during the forecast period is primarily driven by the increasing application of cell therapies, progress in immunomodulators, better early detection techniques, established treatment guidelines, and wider adoption in oncology. Important trends for this period include the rising use of il-6 inhibitors, the broadening scope of crs management in car-t therapy, a greater emphasis on early intervention protocols, the growth of intensive care monitoring, and the creation of targeted immunomodulators.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24199&type=smp

What Key Drivers Are Influencing The Growth Of The Cytokine Release Syndrome Management Market?

The future expansion of the cytokine release syndrome management market is anticipated to be driven by the growing adoption of targeted therapies. These therapies are medications or interventions specifically designed to impede cancer proliferation and dissemination by disrupting molecular targets implicated in tumor formation. The rising application of targeted therapies stems mainly from their capacity to accurately identify and attack cancer cells, thereby minimizing harm to healthy tissues, enhancing treatment effectiveness, and lessening adverse reactions in contrast to conventional treatments. Effective management of cytokine release syndrome is crucial for maximizing the benefits of targeted therapies, as it controls severe inflammatory responses, consequently boosting the safety and efficacy of treatments like CAR-T cell therapy and immune checkpoint inhibitors. As an illustration, data from the American Society of Gene and Cell Therapy, a US-based organization dedicated to gene and cell therapy, indicated that in January 2024, the fourth quarter of 2023 saw a 10% increase in the count of gene therapies undergoing Phase III clinical trials. This represented the initial quarterly uptick of its nature since the third quarter of 2022. Consequently, the expanding deployment of targeted therapies is fueling the expansion of the cytokine release syndrome management market.

What Major Segment Divisions Exist Within The Cytokine Release Syndrome Management Market?

The cytokine release syndrome management market covered in this report is segmented –

1) By Treatment Type: Monoclonal Antibodies, Corticosteroids, Intravenous Immunoglobulin (IVIG), Targeted Therapy, Supportive Care, Other Treatment Types

2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Immune Checkpoint Inhibitors, Hematopoietic Stem Cell Transplantation (HSCT), Autoimmune Diseases, Infections, Other Indications

3) By Route Of Administration: Intravenous (IV), Subcutaneous (SC), Oral, Intramuscular (IM), Intrathecal, Other Routes Of Administration

4) By End Users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Research Institutions, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Tocilizumab, Siltuximab, Infliximab, Rituximab

2) By Corticosteroids: Dexamethasone, Prednisone, Methylprednisolone, Hydrocortisone

3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin, Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin, Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin, Polyvalent Intravenous Immunoglobulin

4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors, Interleukin-6 (IL-6) Inhibitors, Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors, Bruton’s Tyrosine Kinase (BTK) Inhibitors

5) By Supportive Care: Antipyretic Medications, Analgesic Medications, Intravenous Fluids And Electrolyte Solutions, Oxygen Therapy, Vasopressor Agents

6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange), Antihistamine Medications, Leukapheresis, Experimental Therapies, Nutritional Support

Which Market Trends Are Creating New Opportunities In The Cytokine Release Syndrome Management Market?

Key players within the cytokine release syndrome management market are dedicating efforts to clinical trials, with the goal of developing novel treatments, including host-directed small molecule drugs. These therapies seek to modulate the immune response and diminish the intensity of cytokine storms while preserving the body’s capacity to combat infections or cancer. A host-directed small molecule drug is defined as a low molecular weight compound engineered to target the host’s immune signaling pathways, thereby inhibiting excessive cytokine production. This mechanism aids in the management of cytokine release syndrome (CRS) by averting the overactivation of the immune system. Illustrating this trend, in April 2025, the US-based biotechnology firm CytoAgents Inc. reported the successful conclusion of the initial dose-escalation cohort in its Phase 1b/2a clinical trial for CTO1681. This specific host-directed small molecule drug is being developed to both prevent and treat CRS in individuals undergoing CAR T-cell therapy. The experimental treatment showed a positive safety profile, exhibiting no dose-limiting toxicities and no negative impact on CAR T-cell effectiveness. The ongoing trial, which employs a rolling six dose-escalation approach, is designed to evaluate the safety, tolerability, and preliminary efficacy of CTO1681, in addition to determining the appropriate phase 2 dose.

Which Companies Are Leading Innovation In The Cytokine Release Syndrome Management Market?

Major companies operating in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., Humanigen Inc.

Read the full cytokine release syndrome management market report here:

https://www.thebusinessresearchcompany.com/report/cytokine-release-syndrome-management-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Cytokine Release Syndrome Management Market?

North America was the largest region in the cytokine release syndrome management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cytokine release syndrome management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cytokine Release Syndrome Management Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24199&type=smp

Browse Through More Reports Similar to the Global Cytokine Release Syndrome Management Market 2026, By The Business Research Company

Sustained Release Excipients Global Market Report

https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report

Leukocyte Adhesion Deficiency Management Global Market Report

https://www.thebusinessresearchcompany.com/report/leukocyte-adhesion-deficiency-management-global-market-report

Release Agents Global Market Report

https://www.thebusinessresearchcompany.com/report/release-agents-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795